New drug combo aims to spare kidneys in High-Risk urinary tract cancer
NCT ID NCT05912816
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests two drugs—RC48 and Tislelizumab—given before kidney-sparing surgery in 20 people with high-risk upper tract urothelial carcinoma. The goal is to control the cancer while preserving the kidney, avoiding complete removal. Researchers will track how long patients stay cancer-free without losing the kidney.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RC48 (disitamab vedotin) combined with tislelizumab
What this could lead to
If successful, this approach could allow patients with high-risk upper tract cancer to keep their kidney while controlling the disease, avoiding complete kidney removal.
What could go wrong
This is a small, early-phase trial with only 20 participants. The combination therapy may cause side effects, and it is not yet proven to be better than standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UPPER URINARY TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ethics Committee of Shanghai Renji Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••